Business
Tempus wins USD 9.5m in ARPA-H funding to develop autonomous cardiology AI
Tempus AI (Nasdaq: TEM) secured up to USD 9.5 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop and clinically validate an...
Lee's Pharm picks up 1cBio's preclinical PARP1 inhibitor for China and SE Asia
Lee's Pharmaceutical Holdings (HKEX: 00950) has licensed exclusive rights to develop, manufacture, and commercialize OC-3, a preclinical selective PARP1...
Stanford spinout TwoStep raises USD 62.5m as lead peptide-drug conjugate clears FDA IND
San Carlos, California-based TwoStep Therapeutics has raised USD 62.5 million in an oversubscribed Series A financing round, coinciding with US FDA...
Kura launches Caspian with USD 50m to advance menin inhibition in diabetes
A USD 50 million financing round has backed the launch of Caspian Therapeutics, a newly formed company spun out of San Diego-based Kura Oncology (Nasdaq:...
Harbour Bio partner Solstice raises USD 225m to advance CTLA-4 antibody in neoadjuvant cancer
Boston-based Solstice Oncology launched with a USD 225 million Series A financing to advance porustobart (HBM4003), an Fc-enhanced CTLA-4 antibody that...
Schrödinger spins out Tectora with USD 55m Series A for immunology programs
Schrödinger (Nasdaq: SDGR) has licensed two early-stage small molecule immunology and inflammation programs to Tectora Therapeutics, a newly formed...
Assembly Bio converts HSV program from royalty deal to 40% US profit-share with Gilead
Assembly Biosciences (Nasdaq: ASMB) has exercised its embedded option to co-share 40% of US development costs and profits for the herpes simplex virus (HSV)...
Korsana goes public with USD 380m raise and Alzheimer's antibody poised for Phase I
Waltham, Massachusetts-based Korsana Biosciences (Nasdaq: KRSA) has completed its reverse merger with Cyclerion Therapeutics and closed a USD 380 million...
Sernova, Seraxis merge to build integrated stem cell islet replacement platform for T1D
Canada-based Sernova Biotherapeutics Inc. (TSX: SVA) and Germantown, Maryland-based Seraxis Holdings, Inc. have signed a definitive merger agreement to...
Cloverleaf Bio lands USD 33m seed with Lilly, AbbVie, and Boehringer backing
Connecticut-based Cloverleaf Bio has raised USD 33 million in an oversubscribed seed financing round to advance a platform of engineered transfer RNA...
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC
New Jersey-based PDS Biotechnology Corporation (Nasdaq: PDSB) has raised up to USD 22.55 million in a private investment in public equity (PIPE) transaction...
Moonwalk Bio raises USD 70m Series B for adipose-targeted obesity therapies
South San Francisco-based Moonwalk Biosciences has closed an oversubscribed USD 70 million Series B financing to advance a pipeline of adipose-targeted RNA...
BrainChild Bio raises USD 116m to advance CAR T therapy for pediatric brain cancer
Seattle-based BrainChild Bio, Inc., a clinical-stage company developing CAR T cell therapies for central nervous system tumors, has closed a USD 116 million...
Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch
Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced a non-dilutive senior secured term loan facility of up to USD 400 million with...
NeuShen lands USD 80m+ Series B for CNS expansion
With three central nervous system (central nervous system, or CNS) clinical-stage programs under way up to Phase II, China-based NeuShen Therapeutics...
The AllSci Brief
Free, systematic R&D and deal news. Daily.